Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Propranolol and Vinorelbine for Refractory/Relapsing Solid Tumors in Children
NCT02897986Phase 1Unknown
- Sponsor
- Assistance Publique-Hôpitaux de Marseille
- Start
- Jan 2017
- Primary completion
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of propranolol in solid tumor, low-grade glioma (LGG) and desmoid tumor, sponsored by Assistance Publique-Hôpitaux de Marseille. Primary endpoint: Number of patients with grade 3 toxicity at 28 days. Status: unknown.
02
Drugs
propranolol
03
Conditions
solid tumorlow-grade glioma (LGG)desmoid tumor
Beyond the preview
Go deeper on NCT02897986.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02897986.